Imugene: Phase II Ready Drug Targeting Gastric Cancer

Mar. 1, 2016
Dave Gentry, host of "The RedChip Money Report", interviews Leslie Chong, COO of Imugene (ASX: IMU). Imugene (ASX: IMU) is an immuno-oncology ...

 Read More

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market